{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T09:28:59Z","timestamp":1770888539303,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T00:00:00Z","timestamp":1604102400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T00:00:00Z","timestamp":1604102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Institute for the Medical Research Development, Tehran, Iran","award":["943673"],"award-info":[{"award-number":["943673"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Dermatol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Pemphigus is a potentially fatal disease if left untreated. Valid scoring systems and defined cut-off values for classification of patients would help with better management through specified pharmaceutical and non-pharmaceutical treatments.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this study, pemphigus patients who were receiving immunosuppressive treatments and had recent disease relapse were recruited for examination of pemphigus disease area index(PDAI), autoimmune bullous skin disorder intensity score\u00a0(ABSIS), physician global assessment\u00a0(PGA), autoimmune bullous disease quality of life\u00a0(ABQoL), anti-desmoglein 1\u00a0(anti-Dsg1), and anti-Dsg3 autoantibody titers from December-2017 to February-2018. Cut-off values were estimated using model-based clustering classification and the 25th and 75th percentiles approach, performed separately for the exclusive cutaneous, exclusive mucosal, and mucocutaneous groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the 109 included patients, the 25th and 75th percentiles cut-offs were 6.2 and 27 for PDAI score, and 4 and 29.5 for ABSIS score. The model-based analysis resulted in two groups\u00a0(cut-point:15) for PDAI score, and three groups (cut-points:6.4 and 31.5) for ABSIS score. The groups were significantly different for the PDAI, ABSIS, PGA, and ABQoL values. Based on anti-Dsg1 autoantibody values, the model-based analysis cut-point was 128 and the 25th and 75th percentiles cut-offs were 98 and 182. Anti-Dsg3 autoantibody values did not differentiate between pemphigus severity classes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Estimated cut-off values based on the anti-Dsg1 level, PDAI, and ABSIS scoring systems could be used to classify patients into different severity grades for better management and prognosis.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12895-020-00105-y","type":"journal-article","created":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T13:03:13Z","timestamp":1604149393000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Estimated cut-off values for pemphigus severity classification according to pemphigus disease area index (PDAI), autoimmune bullous skin disorder intensity score (ABSIS), and anti-desmoglein 1 autoantibodies"],"prefix":"10.1186","volume":"20","author":[{"given":"Farnam","family":"Mohebi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soheil","family":"Tavakolpour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Teimourpour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roja","family":"Toosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamidreza","family":"Mahmoudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamran","family":"Balighi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narges","family":"Ghandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Ghiasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedram","family":"Nourmohammadpour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vahideh","family":"Lajevardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robabeh","family":"Abedini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armaghan","family":"Azizpour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Nasimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1020-8895","authenticated-orcid":false,"given":"Maryam","family":"Daneshpazhooh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,31]]},"reference":[{"key":"105_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.26","volume":"3","author":"M Kasperkiewicz","year":"2017","unstructured":"Kasperkiewicz M, et al. Pemphigus. Nat Rev Dis Primers. 2017;3:17026.","journal-title":"Nat Rev Dis Primers"},{"key":"105_CR2","doi-asserted-by":"crossref","unstructured":"Joly P, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol. 2020, 1900;34(9):\u201313.","DOI":"10.1111\/jdv.16752"},{"issue":"4","key":"105_CR3","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1001\/jamadermatol.2014.3513","volume":"151","author":"VL Pascoe","year":"2015","unstructured":"Pascoe VL, et al. Using the physician global assessment in a clinical setting to measure and track patient outcomes. JAMA Dermatol. 2015;151(4):375\u201381.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"105_CR4","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ijwd.2016.10.003","volume":"2","author":"S Hanna","year":"2016","unstructured":"Hanna S, Kim M, Murrell DF. Validation studies of outcome measures in pemphigus. Int J Women\u2019s Dermatol. 2016;2(4):128\u201339.","journal-title":"Int J Women\u2019s Dermatol"},{"issue":"10","key":"105_CR5","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1038\/jid.2009.72","volume":"129","author":"M Rosenbach","year":"2009","unstructured":"Rosenbach M, et al. Reliability and convergent validity of two outcome instruments for pemphigus. J Invest Dermatol. 2009;129(10):2404\u201310.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"105_CR6","first-page":"4","volume":"17","author":"M Pfutze","year":"2007","unstructured":"Pfutze M, et al. Introducing a novel autoimmune bullous skin disorder intensity score (ABSIS) in pemphigus. Eur J Dermatol. 2007;17(1):4\u201311.","journal-title":"Eur J Dermatol"},{"issue":"1","key":"105_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/1346-8138.12711","volume":"42","author":"CY Zhao","year":"2015","unstructured":"Zhao CY, Murrell DF. Outcome measures for autoimmune blistering diseases. J Dermatol. 2015;42(1):31\u20136.","journal-title":"J Dermatol"},{"issue":"1","key":"105_CR8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jid.2018.04.042","volume":"139","author":"V Hebert","year":"2019","unstructured":"Hebert V, et al. Large international validation of ABSIS and PDAI pemphigus severity scores. J Invest Dermatol. 2019;139(1):31\u20137.","journal-title":"J Invest Dermatol"},{"key":"105_CR9","unstructured":"Murrell DF, et al. Diagnosis and Management of Pemphigus: recommendations by an international panel of experts. J Am Acad Dermatol. 2018."},{"issue":"1","key":"105_CR10","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.advms.2016.07.002","volume":"62","author":"A Kalinska-Bienias","year":"2017","unstructured":"Kalinska-Bienias A, et al. Measuring of quality of life in autoimmune blistering disorders in Poland. Validation of disease \u2013 specific autoimmune bullous disease quality of life (ABQOL) and the treatment autoimmune bullous disease quality of life (TABQOL) questionnaires. Adv Med Sci. 2017;62(1):92\u20136.","journal-title":"Adv Med Sci"},{"key":"105_CR11","doi-asserted-by":"crossref","unstructured":"Teimourpour A, et al. Autoimmune Bullous Disease Quality of Life (ABQOL) Questionnaire: Validation of the translated Persian version in pemphigus vulgaris. Int J Womens Dermatology. 2020.","DOI":"10.1016\/j.ijwd.2020.03.043"},{"key":"105_CR12","doi-asserted-by":"publisher","DOI":"10.21236\/ADA456562","volume-title":"MCLUST version 3: an R package for normal mixture modeling and model-based clustering","author":"C Fraley","year":"2006","unstructured":"Fraley C, Raftery AE. MCLUST version 3: an R package for normal mixture modeling and model-based clustering. Washington: University Seattle Department of Statistics; 2006."},{"issue":"1","key":"105_CR13","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/bjd.14405","volume":"175","author":"C Boulard","year":"2016","unstructured":"Boulard C, et al. Calculation of cut-off values based on the autoimmune bullous skin disorder intensity score (ABSIS) and pemphigus disease area index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus. Br J Dermatol. 2016;175(1):142\u20139.","journal-title":"Br J Dermatol"},{"issue":"11","key":"105_CR14","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/1346-8138.12649","volume":"41","author":"T Shimizu","year":"2014","unstructured":"Shimizu T, et al. Grading criteria for disease severity by pemphigus disease area index. J Dermatol. 2014;41(11):969\u201373.","journal-title":"J Dermatol"},{"issue":"5","key":"105_CR15","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1001\/archdermatol.2009.9","volume":"145","author":"C Abasq","year":"2009","unstructured":"Abasq C, et al. ELISA testing of anti\u2013desmoglein 1 and 3 antibodies in the management of pemphigus. Arch Dermatol. 2009;145(5):529\u201335.","journal-title":"Arch Dermatol"},{"issue":"6","key":"105_CR16","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.jaad.2017.07.012","volume":"77","author":"LN Albers","year":"2017","unstructured":"Albers LN, et al. Developing biomarkers for predicting clinical relapse in pemphigus patients treated with rituximab. J Am Acad Dermatol. 2017;77(6):1074\u201382.","journal-title":"J Am Acad Dermatol"},{"key":"105_CR17","doi-asserted-by":"crossref","unstructured":"Didona D, et al. Pemphigus: current and future therapeutic strategies. Front Immunol. 2019;10.","DOI":"10.3389\/fimmu.2019.01418"},{"issue":"6","key":"105_CR18","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.jaad.2015.10.051","volume":"74","author":"M Daneshpazhooh","year":"2016","unstructured":"Daneshpazhooh M, et al. Immunologic prediction of relapse in patients with pemphigus vulgaris (PV) in clinical remission. J Am Acad Dermatol. 2016;74(6):1160\u20135.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"105_CR19","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/cia2.12089","volume":"2","author":"M Mobarakabadi","year":"2019","unstructured":"Mobarakabadi M, et al. Evaluation of the possible association between acantholysis and anti-desmogleins 1 and 3 values in pemphigus vulgaris and pemphigus foliaceus. J Cutan Immunol Allergy. 2019;2(6):169\u201373.","journal-title":"J Cutan Immunol Allergy"},{"issue":"6","key":"105_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12671","volume":"31","author":"K Balighi","year":"2018","unstructured":"Balighi K, et al. Anti-desmoglein-1 levels as predictor of prednisolone tapering in pemphigus vulgaris patients treated with rituximab. Dermatol Ther. 2018;31(6):e12671.","journal-title":"Dermatol Ther"},{"issue":"1","key":"105_CR21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/ced.12187","volume":"39","author":"M Daneshpazhooh","year":"2014","unstructured":"Daneshpazhooh M, et al. Comparison of desmoglein 1 and 3 enzyme-linked immunosorbent assay and direct immunofluorescence for evaluation of immunological remission in pemphigus vulgaris. Clin Exp Dermatol. 2014;39(1):41\u20137.","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"105_CR22","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.4049\/jimmunol.170.4.2170","volume":"170","author":"K Tsunoda","year":"2003","unstructured":"Tsunoda K, et al. Induction of pemphigus phenotype by a mouse monoclonal antibody against the amino-terminal adhesive interface of desmoglein 3. J Immunol. 2003;170(4):2170\u20138.","journal-title":"J Immunol"},{"issue":"3","key":"105_CR23","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.jdermsci.2013.02.011","volume":"70","author":"K Kamiya","year":"2013","unstructured":"Kamiya K, et al. A higher correlation of the antibody activities against the calcium-dependent epitopes of desmoglein 3 quantified by ethylenediaminetetraacetic acid-treated enzyme-linked immunosorbent assay with clinical disease activities of pemphigus vulgaris. J Dermatol Sci. 2013;70(3):190\u20135.","journal-title":"J Dermatol Sci"},{"issue":"4","key":"105_CR24","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.jaad.2018.03.035","volume":"79","author":"M Daneshpazhooh","year":"2018","unstructured":"Daneshpazhooh M, et al. Comparison of ethylenediaminetetraacetic acid-treated desmoglein ELISA and conventional desmoglein ELISA in the evaluation of pemphigus vulgaris in remission. J Am Acad Dermatol. 2018;79(4):768\u201370.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"105_CR25","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.ijwd.2019.05.008","volume":"5","author":"H Alaeen","year":"2019","unstructured":"Alaeen H, et al. Short-term clinical and serological follow-up with conventional and conformational anti-desmoglein antibodies in treatment-na\u00efve and previously treated patients with pemphigus vulgaris after receiving rituximab. Int J Womens Dermatol. 2019;5(5):372\u20137.","journal-title":"Int J Womens Dermatol"},{"issue":"4","key":"105_CR26","doi-asserted-by":"publisher","first-page":"295","DOI":"10.5114\/ada.2017.69306","volume":"34","author":"M Dmochowski","year":"2017","unstructured":"Dmochowski M, Gornowicz-Porowska J, Bowszyc-Dmochowska M. Dew drops on spider web appearance: a newly named pattern of IgG4 deposition in pemphigus with direct immunofluorescence. Adv Dermatol Allergol Post\u0229py Dermatol Alergol. 2017;34(4):295.","journal-title":"Adv Dermatol Allergol Post\u0229py Dermatol Alergol"},{"issue":"6","key":"105_CR27","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1111\/j.1365-2133.2012.11144.x","volume":"167","author":"T Funakoshi","year":"2012","unstructured":"Funakoshi T, et al. Enrichment of total serum IgG4 in patients with pemphigus. Br J Dermatol. 2012;167(6):1245\u201353.","journal-title":"Br J Dermatol"},{"issue":"1","key":"105_CR28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0923-1811(00)00158-4","volume":"26","author":"Y Futei","year":"2001","unstructured":"Futei Y, et al. Predominant IgG4 subclass in autoantibodies of pemphigus vulgaris and foliaceus. J Dermatol Sci. 2001;26(1):55\u201361.","journal-title":"J Dermatol Sci"}],"container-title":["BMC Dermatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12895-020-00105-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12895-020-00105-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12895-020-00105-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,26]],"date-time":"2022-11-26T00:38:35Z","timestamp":1669423115000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcdermatol.biomedcentral.com\/articles\/10.1186\/s12895-020-00105-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,31]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["105"],"URL":"https:\/\/doi.org\/10.1186\/s12895-020-00105-y","relation":{},"ISSN":["1471-5945"],"issn-type":[{"value":"1471-5945","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,31]]},"assertion":[{"value":"19 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Committee of Ethics of the National Institute for the Medical Research Development, Tehran, Iran (Ref: 943673). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed written consent was obtained from all individual participants included in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}